Ceapro Inc V.CZO

Diabetes neutraceutical

[prophetoffactz]

CZO's avenanthramide pill trial underway will test blood glucose and insulin levels in fed and non-fed subjects as part of the study. Perhaps that could support CZO's avenanthramide malted technology which allows CZO to access the neutraceutical market for the first time. Last we heard the malted technology had reached commercial scale allowing CZO to produce from one plant what four plants were could produce. 


"Based on our results, we have confirmed for the first time that the glucose uptake is indeed inhibited by the presence of avenanthramides, suggesting the possibility of incorporating avenanthramides in foods to enhance postprandial glucose response, and ultimately improve the management of diabetes." 

 Food Biochem

 

•  
•  
•  

. 2022 Oct;46(10):e14324.

 doi: 10.1111/jfbc.14324. Epub 2022 Jul 27.

The inhibition of intestinal glucose absorption by oat-derived avenanthramides

Haonan Zhouyao 1, Lovemore Nkhata Malunga 1 2 3, Yi Fang Chu 4, Peter Eck 1, Nancy Ames 1 2 3, Sijo Joseph Thandapilly 1 2 3

Affiliations expand

• PMID: 35892210
•  
• DOI: 10.1111/jfbc.14324

Abstract

Avenanthramides are phenolic compounds unique to oats and may contribute to health-promoting properties associated with oat consumption. This study used Xenopus laevis oocytes expressing the glucose transporters, glucose transporter 2 (GLUT2) or sodium-glucose transport protein 1 (SGLT1) and human Caco-2 cells models to investigate the effect of oat avenanthramides on human intestinal glucose transporters. The presence of avenanthramide reduced the glucose uptake in a dose-dependent manner in Caco-2 cells. Glucose uptake in oocytes expressing either GLUT2 or SGLT1 was nullified by oat avenanthramide. There was no significant difference between the inhibition potencies of avenanthramides C and B. Thus, our results suggest that avenanthramides may contribute to the antidiabetic properties of oats. PRACTICAL APPLICATIONS: The present research focus on the antidiabetic properties of avenanthramides, which are unique phenolic compounds found in oats. Inhibiting the activities of the glucose transport proteins expressed in the small intestine is a known strategy to improve the control of postprandial glucose level. We therefore examined the inhibitory effects of avenanthramides on two glucose transporters, glucose transporter 2 and sodium-glucose transport protein 1, predominantly found in the small intestine using the human small intestinal cell model Caco-2 cell line and by heterologously expressing these two transporters in the Xenopus laevis oocytes. Based on our results, we have confirmed for the first time that the glucose uptake is indeed inhibited by the presence of avenanthramides, suggesting the possibility of incorporating avenanthramides in foods to enhance postprandial glucose response, and ultimately improve the management of diabetes. Therefore, future research could consider utilizing this evidence in the development of diabetic-friendly functional foods or nutraceuticals containing avenanthramides.